Jianmin Pharmaceutical GroupLtd Management
Management criteria checks 4/4
Jianmin Pharmaceutical GroupLtd's CEO is Jun Wang, appointed in Sep 2022, has a tenure of 3.08 years. directly owns 0.23% of the company’s shares, worth CN¥14.02M. The average tenure of the management team and the board of directors is 3.1 years and 3.1 years respectively.
Key information
Jun Wang
Chief executive officer
CN¥840.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Anemic Earnings Might Be Worse Than You Think
Mar 29
Investors Holding Back On Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)
Mar 17Potential Upside For Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) Not Without Risk
Nov 10If EPS Growth Is Important To You, Jianmin Pharmaceutical GroupLtd (SHSE:600976) Presents An Opportunity
Sep 25Calculating The Fair Value Of Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976)
Aug 25The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%
Jul 12We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt
Jun 30We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease
May 21We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings
Apr 26CEO
Jun Wang (48 yo)
Mr. Jun Wang was Vice President of KPC Pharmaceuticals,Inc until September 08, 2020. He is Director and President of Jianmin Pharmaceutical Group Co.,Ltd. since September 01, 2022.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | 3.1yrs | CN¥840.30k | 0.23% CN¥ 14.0m | |
| Financial Director | 3.1yrs | CN¥496.20k | 0.055% CN¥ 3.4m | |
| VP & Director | 2.3yrs | CN¥467.10k | no data | |
| Secretary | 3.1yrs | CN¥440.20k | 0.024% CN¥ 1.5m | |
| Vice President | 3.1yrs | CN¥519.20k | 0.12% CN¥ 7.4m | |
| Vice President | 3.1yrs | CN¥530.90k | 0.11% CN¥ 6.5m | |
| Head of Accounting & Accounting Supervisor | no data | no data | no data | |
| Supervisor and Director of Legal & Compliance Department | no data | no data | 0.00033% CN¥ 20.4k |
Experienced Management: 600976's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Director | 3.1yrs | CN¥840.30k | 0.23% CN¥ 14.0m | |
| VP & Director | 2.3yrs | CN¥467.10k | no data | |
| Supervisor and Director of Legal & Compliance Department | 3.1yrs | no data | 0.00033% CN¥ 20.4k | |
| Chairman | 3.1yrs | CN¥2.05m | 0.27% CN¥ 16.6m | |
| Chairman of the Supervisory Board | 3.1yrs | no data | no data | |
| Independent Director | 3.1yrs | CN¥90.00k | no data | |
| Director | 3.1yrs | CN¥60.00k | no data | |
| Director | 3.1yrs | CN¥60.00k | no data | |
| Vice Chairman of the Board | 3.1yrs | CN¥60.00k | no data | |
| Independent Director | 3.1yrs | CN¥90.00k | no data | |
| Supervisor | 3.1yrs | no data | no data | |
| Independent Director | 3.1yrs | CN¥90.00k | no data |
Experienced Board: 600976's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 10:30 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jianmin Pharmaceutical Group Co.,Ltd. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jing Qiang | China International Capital Corporation Limited |
| Xiaoyu Qian | Huatai United Securities Co., Ltd. |